AXL:一种新型的 IBD 治疗靶点。

Q1 Pharmacology, Toxicology and Pharmaceutics
Advances in pharmacology Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI:10.1016/bs.apha.2024.10.009
Bejan J Saeedi, Hannah E Carr, Peter D R Higgins, Calen A Steiner
{"title":"AXL:一种新型的 IBD 治疗靶点。","authors":"Bejan J Saeedi, Hannah E Carr, Peter D R Higgins, Calen A Steiner","doi":"10.1016/bs.apha.2024.10.009","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel diseases (IBD) and their sequela (colitis-associate carcinoma and fibrostenotic complications) remain a significant clinical challenge and novel therapeutic targets are desperately needed. AXL, a receptor tyrosine kinase, has been implicated in myriad cellular functions central to the pathogenesis of IBD. These include facilitating epithelial-to-mesenchymal transition, dampening of Toll-like receptor and natural killer cell mediated immune responses, driving proliferation, and propagating fibrogenic signaling. The vast majority of preclinical research on AXL has focused on its role in cancer. As such, pharmacologic AXL inhibitors are currently in clinical trials, but the indications remain limited to malignancy. In this chapter, we summarize the current preclinical data of AXL in IBD, colitis associated carcinoma, and fibrostenotic disease, and highlight its potential as a novel therapeutic target.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"101 ","pages":"141-157"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AXL: A novel therapeutic target in IBD.\",\"authors\":\"Bejan J Saeedi, Hannah E Carr, Peter D R Higgins, Calen A Steiner\",\"doi\":\"10.1016/bs.apha.2024.10.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Inflammatory bowel diseases (IBD) and their sequela (colitis-associate carcinoma and fibrostenotic complications) remain a significant clinical challenge and novel therapeutic targets are desperately needed. AXL, a receptor tyrosine kinase, has been implicated in myriad cellular functions central to the pathogenesis of IBD. These include facilitating epithelial-to-mesenchymal transition, dampening of Toll-like receptor and natural killer cell mediated immune responses, driving proliferation, and propagating fibrogenic signaling. The vast majority of preclinical research on AXL has focused on its role in cancer. As such, pharmacologic AXL inhibitors are currently in clinical trials, but the indications remain limited to malignancy. In this chapter, we summarize the current preclinical data of AXL in IBD, colitis associated carcinoma, and fibrostenotic disease, and highlight its potential as a novel therapeutic target.</p>\",\"PeriodicalId\":7366,\"journal\":{\"name\":\"Advances in pharmacology\",\"volume\":\"101 \",\"pages\":\"141-157\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.apha.2024.10.009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.apha.2024.10.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

炎症性肠病(IBD)及其后遗症(结肠炎相关癌变和纤维化并发症)仍然是一项重大的临床挑战,迫切需要新的治疗靶点。AXL是一种受体酪氨酸激酶,与IBD发病机制中的多种细胞功能有关。这些功能包括促进上皮细胞向间质转化、抑制 Toll 样受体和自然杀伤细胞介导的免疫反应、驱动增殖以及传播纤维化信号。有关 AXL 的绝大多数临床前研究都集中于其在癌症中的作用。因此,药理 AXL 抑制剂目前正处于临床试验阶段,但其适应症仍仅限于恶性肿瘤。在本章中,我们将总结 AXL 目前在肠道疾病、结肠炎相关癌和纤维化疾病中的临床前数据,并强调其作为新型治疗靶点的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
AXL: A novel therapeutic target in IBD.

Inflammatory bowel diseases (IBD) and their sequela (colitis-associate carcinoma and fibrostenotic complications) remain a significant clinical challenge and novel therapeutic targets are desperately needed. AXL, a receptor tyrosine kinase, has been implicated in myriad cellular functions central to the pathogenesis of IBD. These include facilitating epithelial-to-mesenchymal transition, dampening of Toll-like receptor and natural killer cell mediated immune responses, driving proliferation, and propagating fibrogenic signaling. The vast majority of preclinical research on AXL has focused on its role in cancer. As such, pharmacologic AXL inhibitors are currently in clinical trials, but the indications remain limited to malignancy. In this chapter, we summarize the current preclinical data of AXL in IBD, colitis associated carcinoma, and fibrostenotic disease, and highlight its potential as a novel therapeutic target.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in pharmacology
Advances in pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
9.10
自引率
0.00%
发文量
45
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信